Interstitial Cystitis Painful Bladder Syndrome-Pipeline Review, H1 2016

Interstitial Cystitis Painful Bladder Syndrome-Pipeline Review, H1 2016


  • Products Id :- GMDHC7747IDB
  • |
  • Pages: 100
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Review, H1 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects

The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Interstitial Cystitis (Painful Bladder Syndrome) Overview 8

Therapeutics Development 9

Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome)-Overview 9

Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome)-Comparative Analysis 10

Interstitial Cystitis (Painful Bladder Syndrome)-Therapeutics under Development by Companies 11

Interstitial Cystitis (Painful Bladder Syndrome)-Therapeutics under Investigation by Universities/Institutes 12

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Interstitial Cystitis (Painful Bladder Syndrome)-Products under Development by Companies 16

Interstitial Cystitis (Painful Bladder Syndrome)-Products under Investigation by Universities/Institutes 17

Interstitial Cystitis (Painful Bladder Syndrome)-Companies Involved in Therapeutics Development 18

Afferent Pharmaceuticals, Inc. 18

Allergan Plc 19

Aquinox Pharmaceuticals Inc. 20

Astellas Pharma Inc. 21

Kytogenics Pharmaceuticals, Inc. 22

Lipella Pharmaceuticals, Inc. 23

MediPost Co., Ltd. 24

Qu Biologics Inc. 25

UCB S.A. 26

Urigen Pharmaceuticals, Inc. 27

UroGen Pharmaceuticals, Ltd. 28

Interstitial Cystitis (Painful Bladder Syndrome)-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

(heparin + lidocaine)-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

AF-219-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AQX-1125-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ASP-6294-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Cartistem-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

certolizumab pegol-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

GM-0111-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

lidocaine hydrochloride-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

LP-08-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

mesalamine-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

NEO-5024-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NEO-5937-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

onabotulinumtoxin A-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

onabotulinumtoxinA SR-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

pentosan polysulfate sodium-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

QBECP-SSI-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Interstitial Cystitis (Painful Bladder Syndrome)-Recent Pipeline Updates 76

Interstitial Cystitis (Painful Bladder Syndrome)-Dormant Projects 90

Interstitial Cystitis (Painful Bladder Syndrome)-Discontinued Products 91

Interstitial Cystitis (Painful Bladder Syndrome)-Product Development Milestones 92

Featured News & Press Releases 92

Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 92

Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration 93

Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 93

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis 94

Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 94

Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results from Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 95

Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 96

Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 96

May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 96

Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 98

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2016 9

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome)-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 29

Number of Products by Targets, H1 2016 31

Number of Products by Stage and Targets, H1 2016 31

Number of Products by Mechanism of Actions, H1 2016 33

Number of Products by Stage and Mechanism of Actions, H1 2016 33

Number of Products by Routes of Administration, H1 2016 35

Number of Products by Stage and Routes of Administration, H1 2016 35

Number of Products by Molecule Types, H1 2016 37

Number of Products by Stage and Molecule Types, H1 2016 37

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2016 9

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome)-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 18

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Allergan Plc, H1 2016 19

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 20

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Astellas Pharma Inc., H1 2016 21

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2016 22

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Lipella Pharmaceuticals, Inc., H1 2016 23

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by MediPost Co., Ltd., H1 2016 24

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Qu Biologics Inc., H1 2016 25

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by UCB S.A., H1 2016 26

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by Urigen Pharmaceuticals, Inc., H1 2016 27

Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 28

Assessment by Monotherapy Products, H1 2016 29

Assessment by Combination Products, H1 2016 30

Number of Products by Stage and Target, H1 2016 32

Number of Products by Stage and Mechanism of Action, H1 2016 34

Number of Products by Stage and Route of Administration, H1 2016 36

Number of Products by Stage and Molecule Type, H1 2016 38

Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics-Recent Pipeline Updates, H1 2016 76

Interstitial Cystitis (Painful Bladder Syndrome)-Dormant Projects, H1 2016 90

Interstitial Cystitis (Painful Bladder Syndrome)-Discontinued Products, H1 2016 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Afferent Pharmaceuticals, Inc. Allergan Plc Aquinox Pharmaceuticals Inc. Astellas Pharma Inc. Kytogenics Pharmaceuticals, Inc. Lipella Pharmaceuticals, Inc. MediPost Co., Ltd. Qu Biologics Inc. UCB S.A. Urigen Pharmaceuticals, Inc. UroGen Pharmaceuticals, Ltd.

Interstitial Cystitis (Painful Bladder Syndrome) Therapeutic Products under Development, Key Players in Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics, Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Overview, Interstitial Cystitis (Painful Bladder Syndrome) Pipeline, Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com